Name: Roy Gerona

Qualification: PhD

Country: United States

Affiliation:

University of California,
San Francisco.

Email: Send an Email


Address:

505 Parnassus Ave,
Moffitt Hospital M879B,
San Francisco, CA 94143.

Research Interests:

  • Analytical Toxicology
  • Clinical Toxicology
  • Novel Psychoactive Substances (Designer Drugs)
  • Metabolic profiling of designer drugs

Biography:

  • Dr. Gerona received his Ph.D. in Biochemistry from the University of Wisconsin, Madison where he worked on synaptic vesicles and large dense core vesicle exocytosis with Thomas Martin.
  • He then trained as Post-Doctoral Fellow with Alan Wu at San Francisco General Hospital- University of California, San Francisco under a COMACC- accredited program in Clinical Chemistry and Pharmacogenomics.
  • Dr. Gerona's work during his fellowship focused on the clinical applications of liquid chromatography-time-of-flight mass spectrometry with emphasis on developing methods to support emergency intoxication testing.
  • He is continuing this work, currently focusing on the analysis of novel psychoactive substances (NPS) intoxications through his collaborations with various Poison Control Centers, the Drug Enforcement Administration, and the Department of Homeland Security. 
  • Dr. Gerona runs the Clinical Toxicology and Environmental Biomonitoring Laboratory and the HIV and TB Hair Analysis Laboratory at UCSF.
  • His laboratory also serves as the analytical core for the Program on Reproductive Health and the Environment (PRHE). Through collaborative work with various medical toxicologists, pharmacists, pharmacologists, chemists, and public health experts, Dr. Gerona's laboratory has been analyzing biological samples obtained from suspected NPS cases across the United States in the last five years.
  • His laboratory has also actively conducted collaborative studies on a variety of toxicology-related subjects including surveillance studies on NPS use in raves and electronic dance festivals, surveillance of drugs of abuse in trauma cases, cross-reactivity of designer drugs with immunoassay screens for common drugs of abuse, stability of various prescription and designer drugs, occupational exposure to synthetic cannabinoids, and quantitative analysis of "research chemicals" obtained through the internet among others.
  • Most recently his laboratory has started collaborative work on the pharmacological characterization of synthetic cannabinoids associated with acute intoxications along with "prophetic" structures that may have cannabimimetic properties.